View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 13, 2022

AbbVie reports positive data from Phase II myelofibrosis therapy trial

The trial assessed the efficacy and tolerability of navitoclax alone or with ruxolitinib for myelofibrosis treatment.

AbbVie has reported positive data from the Phase II REFINE clinical trial of its investigational therapy navitoclax with ruxolitinib to treat myelofibrosis patients. 

An oral inhibitor of BCL-XL/BCL-2, navitoclax can stimulate programmed cell death (apoptosis) in cancer cells while ruxolitinib is an inhibitor of JAK1/2.

The multicentre, open-label trial has been designed to assess the efficacy and tolerability of navitoclax alone or in combination with ruxolitinib for treating myelofibrosis patients.

The percentage of subjects who attained Spleen Volume Reduction of greater than or equal to 35% (SVR35) from baseline to week 24 was the primary outcome measure of the trial.

Percentage of subjects attaining a 50% decline in Total Symptom Score from baseline to week 24 and variation in grade of bone marrow fibrosis as evaluated on the European Consensus Grading System were included as the secondary outcomes measures.

According to data from an exploratory analysis of 34 subjects, 38% of them, evaluable for bone marrow fibrosis (BMF) improvements, had a ≥1 grade improvement at any time point in the trial.

For driver gene variant allele frequency (VAF) decline, 26 subjects were evaluable and 23% attained a ≥20% decline at week 24. 

In the trial, five subjects attained both BMF and VAF responses. 

Anti-fibrosis activity evaluated by reversal of BMF and decline in driver gene VAF are recommended as potential biomarkers to assess disease modification in myelofibrosis.

Furthermore, median overall survival (OS) for all subjects was not attained while 100% of the subjects had a minimum of one adverse event (AE).

Thrombocytopenia, diarrhoea, fatigue and nausea were observed to be the most common AEs of any grade.

AbbVie oncology clinical development vice-president and global head Mohamed Zaki said: “Disease control with reversal of bone marrow fibrosis is a key objective for improving patient outcomes. 

“That’s why we are especially pleased about these early results of navitoclax in combination with ruxolitinib that indicate its novel mechanism of action of inducing cell death may cause reversal of bone marrow fibrosis and extend survival for patients who respond to treatment.”

A rare blood cancer, myelofibrosis leads to excessive scar tissue formation or fibrosis in the bone marrow. 

In November 2021, the company reported findings from a post-hoc analysis of the Phase III SELECT-BEYOND trial of Rinvoq (upadacitinib) in rheumatoid arthritis patients.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy